Literature DB >> 2293561

Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies.

P X Xing1, K Reynolds, J J Tjandra, X L Tang, I F McKenzie.   

Abstract

Mammary mucins are increased in amounts in breast cancer patient sera, and most anti-breast cancer antibodies react with such mucins. One such mucin is found in human milk fat globule membrane and consists predominantly of O-linked sugars and a protein core. Partial complementary DNA clones for the protein core have recently been obtained. The nucleotide sequence is of interest as it contains a 60-base pair repeat, giving rise to a repeated 20-amino acid sequence (PDTRPAPGSTAPPAHGVTSA). Peptides with various lengths were synthesized using this sequence and the adjacent 4 amino acids (PDTR). Three anti-human milk fat globule membrane antibodies produced in our laboratory (BC1, BC2, and BC3) were tested to determine their reactivity with these synthetic peptides. Using three different assays (direct enzyme-linked immunosorbent assay test on peptides, direct enzyme-linked immunosorbent assay test on bovine serum albumin-conjugated peptides, and an inhibition test with the peptides in liquid, rather than solid phase), it was shown that APDTR was the minimum amino acid sequence required to form a reactive epitope with all 3 antibodies, although individual differences in the reactivities of the antibodies were noted. The addition of alanine (A) converted a nonreactive PDTR peptide to a reactive one, and the deletion of arginine (R) did the reverse; thus APDTR is the smallest peptide which reacts with these anti-human milk fat globule membrane antibodies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293561

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions.

Authors:  P X Xing; K Reynolds; G A Pietersz; I F McKenzie
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

2.  Characterization of mucin glycoprotein-specific translation products from swine and human trachea, pancreas and colon.

Authors:  S Sangadala; P Wallace; J Mendicino
Journal:  Mol Cell Biochem       Date:  1991-07-24       Impact factor: 3.396

3.  Sialyl-Lewis x and Sialyl-Lewis a are associated with MUC1 in human endometrium.

Authors:  N A Hey; J D Aplin
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

4.  Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells.

Authors:  G Pecher; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

5.  CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.

Authors:  P L Devine; M A Duroux; R J Quin; M A McGuckin; G J Joy; B G Ward; C W Pollard
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

6.  The expression of human FUT1 in HT-29/M3 colon cancer cells instructs the glycosylation of MUC1 and MUC5AC apomucins.

Authors:  Anna López-Ferrer; Carme de Bolós
Journal:  Glycoconj J       Date:  2002-01       Impact factor: 2.916

7.  Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

Authors:  Vasso Apostolopoulos; Geoffrey A Pietersz; Anastasios Tsibanis; Annivas Tsikkinis; Heleni Drakaki; Bruce E Loveland; Sara J Piddlesden; Magdalena Plebanski; Dodie S Pouniotis; Michael N Alexis; Ian F McKenzie; Stamatis Vassilaros
Journal:  Breast Cancer Res       Date:  2006-06-15       Impact factor: 6.466

8.  Monoclonal antibodies reacting with the MUC2 mucin core protein.

Authors:  P L Devine; M A McGuckin; G W Birrell; R H Whitehead; G P Sachdev; P Shield; B G Ward
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

9.  Occult axillary node metastases in breast cancer: their detection and prognostic significance.

Authors:  M A McGuckin; M C Cummings; M D Walsh; B G Hohn; I C Bennett; R G Wright
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

10.  A novel monoclonal antibody specific for sialylated MUC1 mucin.

Authors:  M Yamamoto; V P Bhavanandan; S Nakamori; T Irimura
Journal:  Jpn J Cancer Res       Date:  1996-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.